Administration of zoledronic acid 4 mg given as a 5-minute intravenous infusion has been shown to result in an increased risk of renal toxicity, as measured by increases in serum creatinine, which can progress to renal failure. The incidence of renal toxicity and renal failure has been shown to be reduced when zoledronic acid 4 mg is given as a 15-minute intravenous infusion. Zoledronic acid should be administered by intravenous infusion over no less than 15 minutes [see Warnings and Precautions (5.3), Dosage and Administration (2.4)].
The most frequently observed adverse events were fever, nausea, constipation, anemia, and dyspnea (see Table 4).
Table 4 provides adverse events that were reported by 10% or more of the 189 patients treated with zoledronic acid 4 mg or pamidronate 90 mg from the two HCM trials. Adverse events are listed regardless of presumed causality to study drug.
Table 4: Percentage of Patients With Adverse Events Greater Than or Equal to 10% Reported in Hypercalcemia of Malignancy Clinical Trials by Body System | Zoledronic Acid 4 mg n (%) | Pamidronate 90 mg n (%) |
Patients Studied | | | | |
Total No. of Patients Studied | 86 | (100) | 103 | (100) |
Total No. of Patients with any AE | 81 | (94) | 95 | (92) |
Body as a Whole | | | | |
Fever | 38 | (44) | 34 | (33) |
Progression of Cancer | 14 | (16) | 21 | (20) |
Cardiovascular | | | | |
Hypotension | 9 | (11) | 2 | (2) |
Digestive | | | | |
Nausea | 25 | (29) | 28 | (27) |
Constipation | 23 | (27) | 13 | (13) |
Diarrhea | 15 | (17) | 17 | (17) |
Abdominal Pain | 14 | (16) | 13 | (13) |
Vomiting | 12 | (14) | 17 | (17) |
Anorexia | 8 | (9) | 14 | (14) |
Hemic and Lymphatic System | | | | |
Anemia | 19 | (22) | 18 | (18) |
Infections | | | | |
Moniliasis | 10 | (12) | 4 | (4) |
Laboratory Abnormalities | | | | |
Hypophosphatemia | 11 | (13) | 2 | (2) |
Hypokalemia | 10 | (12) | 16 | (16) |
Hypomagnesemia | 9 | (11) | 5 | (5) |
Musculoskeletal | | | | |
Skeletal Pain | 10 | (12) | 10 | (10) |
Nervous | | | | |
Insomnia | 13 | (15) | 10 | (10) |
Anxiety | 12 | (14) | 8 | (8) |
Confusion | 11 | (13) | 13 | (13) |
Agitation | 11 | (13) | 8 | (8) |
Respiratory | | | | |
Dyspnea | 19 | (22) | 20 | (19) |
Coughing | 10 | (12) | 12 | (12) |
Urogenital | | | | |
Urinary Tract Infection | 12 | (14) | 15 | (15) |
The following adverse events from the two controlled multicenter HCM trials (n=189) were reported by a greater percentage of patients treated with zoledronic acid 4 mg than with pamidronate 90 mg and occurred with a frequency of greater than or equal to 5% but less than 10%. Adverse events are listed regardless of presumed causality to study drug: asthenia, chest pain, leg edema, mucositis, dysphagia, granulocytopenia, thrombocytopenia, pancytopenia, nonspecific infection, hypocalcemia, dehydration, arthralgias, headache and somnolence.
Rare cases of rash, pruritus, and chest pain have been reported following treatment with zoledronic acid.
In the bone metastases trials, renal deterioration was defined as an increase of 0.5 mg/dL for patients with normal baseline creatinine (less than 1.4 mg/dL) or an increase of 1.0 mg/dL for patients with an abnormal baseline creatinine (greater than or equal to 1.4 mg/dL). The following are data on the incidence of renal deterioration in patients receiving zoledronic acid 4 mg over 15 minutes in these trials (see Table 10).
Table 10: Percentage of Patients With Treatment-Emergent Renal Function Deterioration by Baseline Serum Creatinine*| *Table includes only patients who were randomized to the trial after a protocol amendment that lengthened the infusion duration of zoledronic acid to 15 minutes. |
Patient Population/Baseline Creatinine |
Multiple Myeloma and Breast Cancer | Zoledronic Acid 4 mg | Pamidronate 90 mg |
n/N | (%) | n/N | (%) |
Normal | 27/246 | (11%) | 23/246 | (9%) |
Abnormal | 2/26 | (8%) | 2/22 | (9%) |
Total | 29/272 | (11%) | 25/268 | (9%) |
Solid Tumors | Zoledronic Acid 4 mg | Placebo |
n/N | (%) | n/N | (%) |
Normal | 17/154 | (11%) | 10/143 | (7%) |
Abnormal | 1/11 | (9%) | 1/20 | (5%) |
Total | 18/165 | (11%) | 11/163 | (7%) |
Prostate Cancer | Zoledronic Acid 4 mg | Placebo |
n/N | (%) | n/N | (%) |
Normal | 12/82 | (15%) | 8/68 | (12%) |
Abnormal | 4/10 | (40%) | 2/10 | (20%) |
Total | 16/92 | (17%) | 10/78 | (13%) |
The risk of deterioration in renal function appeared to be related to time on study, whether patients were receiving zoledronic acid (4 mg over 15 minutes), placebo, or pamidronate.
In the trials and in postmarketing experience, renal deterioration, progression to renal failure, and dialysis have occurred in patients with normal and abnormal baseline renal function, including patients treated with 4 mg infused over a 15-minute period. There have been instances of this occurring after the initial zoledronic acid dose.